Cedarbaum JM - Search Results

1

A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials.

Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM. Kasarskis EJ, et al. Among authors: cedarbaum jm. J Neurol Sci. 1999 Oct 31;169(1-2):118-25. doi: 10.1016/s0022-510x(99)00230-0. J Neurol Sci. 1999. PMID: 10540019 Clinical Trial.

2

Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF.

Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Mitsumoto H, et al. Among authors: cedarbaum jm. Science. 1994 Aug 19;265(5175):1107-10. doi: 10.1126/science.8066451. Science. 1994. PMID: 8066451

3

Regional changes of ciliary neurotrophic factor and nerve growth factor levels in post mortem spinal cord and cerebral cortex from patients with motor disease.

Anand P, Parrett A, Martin J, Zeman S, Foley P, Swash M, Leigh PN, Cedarbaum JM, Lindsay RM, Williams-Chestnut RE, et al. Anand P, et al. Among authors: cedarbaum jm. Nat Med. 1995 Feb;1(2):168-72. doi: 10.1038/nm0295-168. Nat Med. 1995. PMID: 7585015

4

Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group.

Stambler N, Charatan M, Cedarbaum JM. Stambler N, et al. Among authors: cedarbaum jm. Neurology. 1998 Jan;50(1):66-72. doi: 10.1212/wnl.50.1.66. Neurology. 1998. PMID: 9443459 Clinical Trial.

5

Disease status and use of ventilatory support by ALS patients. BDNF Study Group.

Cedarbaum JM, Stambler N. Cedarbaum JM, et al. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001 Mar;2(1):19-22. doi: 10.1080/146608201300079373. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001. PMID: 11465928 Clinical Trial.

6

Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials.

Cedarbaum JM, Stambler N. Cedarbaum JM, et al. J Neurol Sci. 1997 Oct;152 Suppl 1:S1-9. doi: 10.1016/s0022-510x(97)00237-2. J Neurol Sci. 1997. PMID: 9419047 Clinical Trial.

7

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. Cedarbaum JM, et al. J Neurol Sci. 1999 Oct 31;169(1-2):13-21. doi: 10.1016/s0022-510x(99)00210-5. J Neurol Sci. 1999. PMID: 10540002 Clinical Trial.

8

Endogenous NGF and CNTF levels in human peripheral nerve injury.

Anand P, Terenghi G, Birch R, Wellmer A, Cedarbaum JM, Lindsay RM, Williams-Chestnut RE, Sinicropi DV. Anand P, et al. Among authors: cedarbaum jm. Neuroreport. 1997 May 27;8(8):1935-8. doi: 10.1097/00001756-199705260-00028. Neuroreport. 1997. PMID: 9223080 Clinical Trial.

9

Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease.

Ikeda K, Klinkosz B, Greene T, Cedarbaum JM, Wong V, Lindsay RM, Mitsumoto H. Ikeda K, et al. Among authors: cedarbaum jm. Ann Neurol. 1995 Apr;37(4):505-11. doi: 10.1002/ana.410370413. Ann Neurol. 1995. PMID: 7717687

10

Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.

Cedarbaum JM, Breck L, Kutt H, McDowell FH. Cedarbaum JM, et al. Neurology. 1987 Oct;37(10):1607-12. doi: 10.1212/wnl.37.10.1607-a. Neurology. 1987. PMID: 3658164

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results